Genetically modified immune cells targeting tumor antigens

Mansour Poorebrahim; Mohammad Foad Abazari; Solmaz Sadeghi; Reza Mahmoudi; Asma Kheirollahi; Hassan Askari; Stina L Wickström; Vahdat Poortahmasebi; Andreas Lundqvist; Rolf Kiessling; Angel Cid-Arregui

doi:10.1016/j.pharmthera.2020.107603

Genetically modified immune cells targeting tumor antigens

Pharmacol Ther. 2020 Oct:214:107603. doi: 10.1016/j.pharmthera.2020.107603. Epub 2020 Jun 15.

Affiliations

¹ Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: mansour.poorebrahim@ki.se.
² Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.
³ Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Department of Medical Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.
⁵ Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
⁶ Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
⁷ Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
⁸ Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Infectious and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Faculty of Medicine, Department of Bacteriology and Virology, Tabriz University of Medical Sciences, Tabriz, Iran.
⁹ Targeted Tumor Vaccines Group, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: a.cid@dkfz.de.

PMID: 32553789
DOI: 10.1016/j.pharmthera.2020.107603

Abstract

Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such 'living' therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy.

Keywords: Genetically modified immune cell; Tumor antigen; ‘Living’ therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antigens, Neoplasm / immunology
Antigens, Neoplasm / metabolism*
B-Lymphocytes / immunology
B-Lymphocytes / metabolism
B-Lymphocytes / transplantation
Dendritic Cells / immunology
Dendritic Cells / metabolism
Dendritic Cells / transplantation*
Genetic Therapy*
Humans
Immunotherapy, Adoptive*
Killer Cells, Natural / immunology
Killer Cells, Natural / metabolism
Killer Cells, Natural / transplantation
Lymphocyte Subsets / immunology
Lymphocyte Subsets / metabolism
Lymphocyte Subsets / transplantation*
Macrophages / immunology
Macrophages / metabolism
Macrophages / transplantation*
Neoplasms / genetics
Neoplasms / immunology
Neoplasms / metabolism
Neoplasms / therapy*
Receptors, Chimeric Antigen / genetics*
Receptors, Chimeric Antigen / immunology
Receptors, Chimeric Antigen / metabolism
T-Lymphocytes / immunology
T-Lymphocytes / metabolism
T-Lymphocytes / transplantation
Treatment Outcome
Tumor Microenvironment

Substances

Antigens, Neoplasm
Receptors, Chimeric Antigen